Mayra (Dienogest, Ethinylestradiol)

The ethinylestradiol component suppresses follicle‑stimulating hormone, while dienogest blocks the luteinizing hormone surge, together preventing ovulation. The formulation also thickens cervical mucus and alters the endometrial lining, creating conditions that are unfavorable for fertilisation and implantation.

The dosing regimen for Mayra is determined by the prescribing clinician based on individual health status and treatment goals. Typically, a standard combined oral contraceptive schedule is followed, but the exact number of tablets per cycle and any placebo days are set by the prescriber.

Mayra is contraindicated during pregnancy because it is intended to prevent conception. If pregnancy occurs, the product should be discontinued. While limited data exist for breastfeeding, combined oral contraceptives are generally used with caution; a healthcare professional should assess the risk‑benefit ratio for nursing mothers.

To request Mayra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any special handling), and necessary import documentation.

Mayra contains the progestogen dienogest, which offers a slightly lower androgenic profile compared with some older progestins, potentially resulting in fewer acne‑related side effects. Its estrogen component, ethinylestradiol, is standard for combined pills, providing comparable contraceptive efficacy and cycle control to other products in the same class.

Mayra tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Mayra is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and should be taken with or without food as directed by the prescriber. Consistent daily intake maximises contraceptive effectiveness.

The most serious risks include venous or arterial thromboembolism, hypertension, severe liver disease, and rare allergic reactions such as anaphylaxis. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be closely monitored or may need alternative contraception.

Mayra is contraindicated in women with known or suspected pregnancy, active thromboembolic disease, uncontrolled hypertension, severe liver disease, or a history of estrogen‑dependent tumors. It should also be avoided by smokers over 35 years of age and by individuals with known hypersensitivity to any component of the tablet.